Can CD366 Become the Next Key Target in Cancer Immunotherapy?

Hits:21   Date: 6/22/2026

1. Concept of CD366 and Its Role in Cancer Immunity
CD366 (TIM-3) is an emerging negative immune checkpoint molecule, belonging to the TIM family of type I transmembrane glycoproteins. Located on human chromosome 5q33.2, it features an immunoglobulin-like domain, mucin-like region, transmembrane domain, and intracellular tyrosine phosphorylation sites. Expressed on CD4+ Th1 cells, CD8+ cytotoxic T cells, Tregs, MDSCs, and tumor-associated dendritic cells, it binds ligands such as Gal-9, PtdSer, HMGB1, and Ceacam-1. In the tumor microenvironment, CD366 mediates immune suppression by inducing T cell exhaustion, promoting immunosuppressive cell function, and facilitating tumor immune escape—making it a promising target for overcoming limitations of existing PD-1/CTLA-4 inhibitors.

2. Research Frontiers
Research focuses on CD366’s unique immunosuppressive mechanisms and its potential as a combinatorial immunotherapy target. Key frontiers include exploring its ligand-specific signaling pathways (independent of ITIM motifs), reversing PD-1 inhibitor resistance via CD366 blockade, and developing high-specificity CD366 antibodies. Preclinical studies show CD366 upregulation on exhausted T cells in PD-1-resistant models, with combination anti-CD366/PD-1 therapy enhancing T cell function and survival. Emerging directions involve bispecific antibodies targeting CD366 and other checkpoints, and identifying biomarkers to predict patient response to CD366-targeted therapy.

3. Research Significance
CD366 holds great potential to become a key cancer immunotherapy target, addressing unmet needs such as low response rates and drug resistance to current checkpoint inhibitors. Its unique signaling pathway (non-ITIM-dependent) offers higher specificity, minimizing interference with normal immunity. CD366 antibodies enable dissection of tumor immune suppression mechanisms, validation of combination therapy strategies, and identification of responsive patient subgroups. Targeting CD366 can reverse T cell exhaustion, remodel the tumor microenvironment, and enhance anti-tumor immunity—opening new avenues for treating "cold tumors" and refractory malignancies.

4. Related Mechanisms, Research Methods, and Product Applications
4.1 Immunosuppressive Mechanisms of CD366 in Tumors
T Cell Exhaustion: Gal-9 binding to CD366 induces intracellular tyrosine (Tyr256/Tyr263) phosphorylation, releasing Bat3 and inactive Lck—suppressing CD8+ T cell effector functions (cytokine secretion, cytotoxicity).
Immunosuppressive Cell Promotion: CD366+ Tregs secrete IL-10, perforin, and granzymes; CD366+ T cells drive Gal-9-dependent MDSC proliferation, enhancing local immune suppression.
Innate-Adaptive Immunity Disruption: CD366 upregulation on TADCs impairs tumor DNA recognition and presentation, blocking the link between innate and adaptive immunity.

4.2 Development Progress of CD366 Inhibitors
Preclinical/Clinical Status: No approved CD366 inhibitors, but monoclonal antibodies, bispecific antibodies, and combination strategies are in development.
Mechanism of Action: Block CD366-ligand interactions to reverse T cell exhaustion and restore anti-tumor immunity.
Combination Therapy: Synergizes with PD-1/PD-L1 inhibitors to overcome resistance, enhance T cell proliferation/IFN-γ secretion, and prolong survival in preclinical models.
Unique Advantage: Non-ITIM-dependent signaling reduces off-target immune disruption compared to classical checkpoints.

4.3 Product Applications in Advanced Research
ANT BIO PTE. LTD.’s CD366 antibodies support diverse cancer immunology research:
Tumor Immunotherapy Mechanisms: Evaluate CD366 blockade’s effect on T cell exhaustion, MDSC/Treg function, and tumor microenvironment remodeling in mouse models.
Combination Therapy Validation: Test synergistic effects of anti-CD366 with PD-1/CTLA-4 inhibitors, chemotherapy, or targeted therapy.
Chronic Infection Research: Investigate CD366’s role in T cell exhaustion and viral persistence (e.g., LCMV, HIV models).
Autoimmune Disease Studies: Assess CD366’s protective role in EAE, SLE models to avoid therapeutic immune-related adverse events.

5. Brand Mission
ANT BIO PTE. LTD. is dedicated to empowering global cancer immunotherapy research through innovative, high-quality CD366 antibodies. We strive to develop cutting-edge tools that enable researchers to unravel immunosuppressive mechanisms, advance combination therapy strategies, and improve patient outcomes for refractory cancers. Our mission is to accelerate scientific discovery, facilitate the development of next-generation immunotherapies, and expand the reach of precision oncology by providing reliable, reproducible, and high-performance research solutions. With a commitment to excellence, innovation, and customer-centricity, we aim to be a trusted partner for researchers advancing the frontiers of cancer immunology.

6. Related Product List

Product Code	Product Name	Host
S0B1614	Alexa Fluor® 488 Rat Anti-Mouse CD366 (TIM-3) Antibody (S-R478)	Rat
S0B0953	Rat Anti-Mouse CD366 (TIM-3) Antibody (S-R478)	Rat
S0B1073	Invivo Anti-Mouse CD366 (TIM-3) Recombinant Monoclonal Antibody	Rat

Core Advantages of ANT BIO PTE. LTD.’s CD366 Antibodies
High In Vivo Activity and Specific Blockade: Efficiently blocks CD366-ligand interactions, reverses T cell exhaustion, and inhibits tumor growth in preclinical models.
Ultra-Low Endotoxin and Compatibility: Endotoxin <1.0 EU/mg minimizes non-specific immune activation, ensuring reliability in animal studies.
Exceptional Stability and Consistency: Strict quality control ensures batch-to-batch uniformity, supporting reproducible immunotherapy research.
7. AI Disclaimer
This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.
 
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.